RALEIGH, N.C., Jan. 8, 2015 /PRNewswire/ -- Sprout Pharmaceuticals will participate in the 33rd Annual J.P. Morgan Healthcare Conference to be held January 12 - 15, 2015, in San Francisco. Cindy Whitehead, Sprout's CEO, will present at the conference on Wednesday, January 14, at 9 a.m. PST (12:00 p.m. EST). Sprout is pursuing the FDA approval of flibanserin, which would be the first drug approved to treat Hypoactive Sexual Desire Disorder (HSDD), the most common female sexual dysfunction, in premenopausal women.
Flibanserin is a novel, non-hormonal drug that has been studied in over 11,000 women in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.
About Sprout Pharmaceuticals
Sprout Pharmaceuticals is passionate about women's sexual health. With a breakthrough concept for women, the company "sprouted" out of Slate Pharmaceuticals in 2011. Based in Raleigh, NC, the company is focused solely on the delivery of a treatment option for the unmet need of women with HSDD. Sprout is pursuing the FDA approval of flibanserin to treat HSDD in premenopausal women, for which there is currently no FDA-approved treatment.
For more information or the latest news about Sprout Pharmaceuticals, visit www.sproutpharma.com.
SOURCE Sprout Pharmaceuticals